A 12-week treatment with fractional CO₂ laser for vulvovaginal atrophy: a pilot study

References

• Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52:S46–52
   PubMed Web of Science ®Google Scholar
• Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric 2009;12:279–85
   PubMed Web of Science ®Google Scholar
• Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
   PubMed Web of Science ®Google Scholar
• Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol 2008;51:549–55
   PubMed Web of Science ®Google Scholar
• Simon JA. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health (Larchmt) 2011;20:1453–65
   PubMed Web of Science ®Google Scholar
• Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;5: 661–6
   Web of Science ®Google Scholar
• Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010; 19:425–32
   PubMed Web of Science ®Google Scholar
• Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133–42
   PubMed Web of Science ®Google Scholar
• Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004;49:292–303
   PubMed Web of Science ®Google Scholar
• Palacios S. Managing urogenital atrophy. Maturitas 2009;63: 315–18
   PubMed Web of Science ®Google Scholar
• Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63: 138–41
   PubMed Web of Science ®Google Scholar
• Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013;5:437–47
   PubMedGoogle Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3–9
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010;67:233–8
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views and Attitudes (VIVA) – results from an international survey. Climacteric 2012;15:36–44
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (Clarifying Vaginal Atrophy’s Impact On Sex and Relationships) Survey: Implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013;10:2232–41
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
   PubMed Web of Science ®Google Scholar
• Rees M, Pérez-López FR, Ceasu I, et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas 2012;73:171–4
   PubMed Web of Science ®Google Scholar
• NAMS. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause 2013;20:888–902
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–30
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O; the Ospemifene Study Group. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17: 173–82
   PubMed Web of Science ®Google Scholar
• Shulman LP, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications or clinical practice. J Womens Health (Larchmt) 2008;17:569–78
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10: 1790–9
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med 2013;10:1567–74
   PubMed Web of Science ®Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006 Oct 18;(4):CD001500
   PubMedGoogle Scholar
• Sadovsky R, Basson R, Krychman M, et al. Cancer and sexual problems. J Sex Med 2010;7:349–73
   PubMed Web of Science ®Google Scholar
• Pruthi S, Simon JA, Early AP. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 2011;17:403–8
   PubMed Web of Science ®Google Scholar
• Sinha A, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric 2013; 16:305–12
   PubMed Web of Science ®Google Scholar
• Berlin AL, Hussain M, Phelps R, Goldberg DJ. A prospective study of fractional scanned nonsequential carbon dioxide laser resurfacing: a clinical and histopathologic evaluation. Dermatol Surg 2009;35:222–8
   PubMed Web of Science ®Google Scholar
• Ong MW, Bashir SJ. Fractional laser resurfacing for acne scars: a review. Br J Dermatol 2012;166:1160–9
   PubMed Web of Science ®Google Scholar
• Tierney EP, Hanke CW. Fractionated carbon dioxide laser treatment of photoaging: prospective study in 45 patients and review of the literature. Dermatol Surg 2011;37:1279–90
   PubMed Web of Science ®Google Scholar
• Tierney EP, Hanke CW. Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature. J Drugs Dermatol 2009;8:723–31
   PubMed Web of Science ®Google Scholar
• Peterson JD, Goldman MP. Rejuvenation of the aging chest: a review and our experience. Dermatol Surg 2011;37:555–71
   PubMed Web of Science ®Google Scholar
• Salvatore S, Digesu G, Siesto G, et al. Vaginal collagen remodelling after fractional carbon dioxide laser surgery [abstract 233]. Presented at Annual Meeting of the International Continence Society, Glasgow, United Kingdom, August–September 2011
   Google Scholar
• Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008;15:885–9
   PubMed Web of Science ®Google Scholar
• Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996;175:10–17
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Notelovitz M, Kelly SJ, et al. Long-term non-hormonal treatment of vaginal dryness. Clin Pract Sexuality 1992;8:3–8
   Google Scholar
• Ware J, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33
   PubMed Web of Science ®Google Scholar
• Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: The challenges ahead. Lancet 2009;374:1196–208
   PubMed Web of Science ®Google Scholar
• Brincat MP, Baron YM, Galea R. Estrogens and the skin. Climacteric 2005;8:110–23
   PubMed Web of Science ®Google Scholar
• Sartori MG, Feldner PC, Jarmy-Di Bella ZI, et al. Sexual steroids in urogynecology. Climacteric 2011;14:5–14
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. on behalf of the International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012;15:267–74
   PubMed Web of Science ®Google Scholar
• Fournier A, Kernaleguen C, Panjo H, Clavel-Chapelon F, Ringa V. Postmenopausal hormone therapy initiation before and after the Women’s Health Initiative in two French cohorts. Menopause 2011;18:219–23
   PubMed Web of Science ®Google Scholar
• Chin SN, Trinkaus M, Simmons C, et al. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer 2009;9:108–17
   PubMed Web of Science ®Google Scholar
• Biglia N, Moggio G, Peano E, et al. Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med 2010;7:1891–900
   PubMed Web of Science ®Google Scholar
• Longo C, Galimberti M, De Pace B, Pellacani G, Bencini PL. Laser skin rejuvenation: epidermal changes and collagen remodeling evaluated by in vivo confocal microscopy. Lasers Med Sci 2013;28:769–76
   PubMed Web of Science ®Google Scholar
• Kohl E, Meierhöfer J, Koller M, et al. Fractional carbon dioxide laser resurfacing of rhytides and photoaging: a prospective study using profilometric analysis. Br J Dermatol 2013;170:858–65
   Web of Science ®Google Scholar
• Doumouchtsis SK, Chrysanthopoulou EL. Urogenital consequences in ageing women. Best Pract Res Clin Obstet Gynaecol 2013;27:699–714
   PubMed Web of Science ®Google Scholar